Skye Bioscience, Inc. (“Skye”) (Nasdaq: SKYE), and Redx Pharma Limited (“Redx”), a U.K. based, privately-held clinical-stage biotechnology company focused on developing novel, small molecule, targeted medicines for fibrotic disease, announce that they have entered into a definitive transaction agreement (the “Transaction Agreement”). The combined company, Fibrx, will focus on advancing certain fibrosis assets of Redx through clinical and pre-clinical development. The lead asset, RXC008, is a potential first-in-class GI-restricted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn’s disease which is now ready to commence a Phase 2 clinical study in patients.
Read the full article: Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125M in Financings //
Source: https://www.globenewswire.com/news-release/2026/08/14/3345392/0/en/skye-bioscience-and-redx-pharma-announce-transaction-agreement-and-125-million-in-financings.html?_gl=1*1cqi0x6*_up*MQ..*_ga*MTI2NTU3MTg1OC4xNzg2NzE1NTg5*_ga_B6167QB2TF*czE3ODY3MTU1ODgkbzEkZzAkdDE3ODY3MTU1ODgkajYwJGwwJGgxODczOTA1NzU1*_ga_ERWPGTJ5X8*czE3ODY3MTU1ODgkbzEkZzAkdDE3ODY3MTU1ODgkajYwJGwwJGgw